DUBLIN–(BUSINESS WIRE)–The “Global Mycosis Fungoides Therapeutics Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
The mycosis fungoides therapeutics market is poised to grow by $ 115.42 mn during 2021-2025, progressing at a CAGR of 5% during the forecast period.
The market is driven by the special drug designations, recent drug approvals and growing incidence of mycosis fungoides.
The report on mycosis fungoides therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The mycosis fungoides therapeutics market analysis includes type segment and geographical landscapes.
This study identifies the strong R&D of pipeline molecule as one of the prime reasons driving the mycosis fungoides therapeutics market growth during the next few years. Also, novel drug delivery system and increasing research funding will lead to sizable demand in the market.
The publisher robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading mycosis fungoides therapeutics market vendors that include Bristol-Myers Squibb Co., Eisai Co. Ltd., Helsinn Healthcare SA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Pfizer Inc., Seagen Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the mycosis fungoides therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers.
Key Topics Covered:
Executive Summary
- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 – 2025
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Small molecules – Market size and forecast 2020-2025
- Biologics – Market size and forecast 2020-2025
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2020-2025
- Europe – Market size and forecast 2020-2025
- Asia – Market size and forecast 2020-2025
- ROW – Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Competitive scenario
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Bristol-Myers Squibb Co.
- Eisai Co. Ltd.
- Helsinn Healthcare SA
- Hikma Pharmaceuticals Plc
- Horizon Therapeutics Plc
- Kyowa Kirin Co. Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- Seagen Inc.
- Takeda Pharmaceutical Co. Ltd.
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/nwu9nc
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900